PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Feedback
Settings

Settings

Goto Application

1. WO2006014958 - PLATELET ACTIVATION MARKERS AS PREDICTORS OF DISEASE AND OF RESPONSE TO THERAPY AND FOR MONITORING THERAPEUTIC PROGRESS

PermaLink
Publication Number WO/2006/014958
Publication Date 09.02.2006
International Application No. PCT/US2005/026496
International Filing Date 26.07.2005
IPC
A61K 35/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
C12Q 1/56 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
56involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G01N 33/86 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
86involving blood coagulating time
CPC
G01N 2333/4737
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4737C-reactive protein
G01N 2800/324
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
32Cardiovascular disorders
324Coronary artery diseases, e.g. angina pectoris, myocardial infarction
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/56972
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
56966Animal cells
56972White blood cells
Applicants
  • BAYER HEALTHCARE LLC [US]/[US] (AllExceptUS)
  • CHAPMAN-MONTGOMERY, Sabrinah, E. [US]/[US] (UsOnly)
  • OKRONGLY, David [US]/[US] (UsOnly)
  • AHNADI, Charaf, E. (UsOnly)
  • WU, Alan [US]/[US] (UsOnly)
  • GERVAIS, Andre (UsOnly)
Inventors
  • CHAPMAN-MONTGOMERY, Sabrinah, E.
  • OKRONGLY, David
  • AHNADI, Charaf, E.
  • WU, Alan
  • GERVAIS, Andre
Agents
  • ELDERKIN, Dianne, B.
Priority Data
60/591,02526.07.2004US
60/603,59423.08.2004US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) PLATELET ACTIVATION MARKERS AS PREDICTORS OF DISEASE AND OF RESPONSE TO THERAPY AND FOR MONITORING THERAPEUTIC PROGRESS
(FR) MARQUEURS D'ACTIVATION DE PLAQUETTES UTILISES COMME PREDICTEURS DE MALADIE ET DE REPONSE A UN TRAITEMENT ET PERMETTANT DE SURVEILLER UNE EVOLUTION THERAPEUTIQUE
front page image
Abstract
(EN) Methods for assessing patient risk for platelet-affected disease states are disclosed. Also disclosed are methods for predicting the appropriateness of platelet antagonist therapy, and for monitoring patients during therapeutic intervention or during a combined regimen of therapy and angioplasty.
(FR) L'invention concerne des procédés permettant d'évaluer le risque pour un patient d'être atteint d'états pathologiques affectant les plaquettes. L'invention concerne également des procédés permettant de prévoir la pertinence d'un traitement antagoniste des plaquettes et de surveiller des patients pendant l'intervention thérapeutique ou pendant un régime combiné de traitement et d'angioplastie.
Related patent documents
EP1814563
US20080311606
US20100173339
Latest bibliographic data on file with the International Bureau
# -